The EGFR is commonly overexpressed in non-small cell lung cancer (in 89% squamous cell carcinoma; 41% adenocarcinomas) (30), and therefore, it is considered a potential target for cancer therapy (30). The gene discussed is EGFR; the disease is squamous cell carcinoma.